Pfizer has leapt to the top of the most active corporate venturing investors in US healthcare deals for the first half of 2016, as Novartis falls out of the top 10.

As ever, bank SVB’s fascinating look into the US venture market in healthcare reveals a host of insights with half of last year’s most active corporate venturing (CVC) units in the first half cutting back significantly at this year’s mid-point.

Whereas Novartis Venture Funds was the most active CVC in the first six months of 2015 with nine US deals, it has fallen out of the top 10 table for the same period in 2016. Similarly, Celgene and GlaxoSmithKline’s SR One have also…